[go: up one dir, main page]

MX2009011207A - Eteres de amidas de acido naftalen-carboxilico como cura para el cancer. - Google Patents

Eteres de amidas de acido naftalen-carboxilico como cura para el cancer.

Info

Publication number
MX2009011207A
MX2009011207A MX2009011207A MX2009011207A MX2009011207A MX 2009011207 A MX2009011207 A MX 2009011207A MX 2009011207 A MX2009011207 A MX 2009011207A MX 2009011207 A MX2009011207 A MX 2009011207A MX 2009011207 A MX2009011207 A MX 2009011207A
Authority
MX
Mexico
Prior art keywords
carboxylic acid
acid amides
ethers
cancer cure
naphtalene
Prior art date
Application number
MX2009011207A
Other languages
English (en)
Inventor
Paul W Manley
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2009011207A publication Critical patent/MX2009011207A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención se relaciona con las amidas de ácido naftalen-carboxílico y ácido isoquinolin-carboxílico, y los compuestos relacionados de la fórmula (I) y sus usos como productos farmacéuticos.
MX2009011207A 2007-04-17 2008-04-17 Eteres de amidas de acido naftalen-carboxilico como cura para el cancer. MX2009011207A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07106308 2007-04-17
PCT/EP2008/054640 WO2008125691A2 (en) 2007-04-17 2008-04-17 Ethers of naphtalene carboxylic acid amides as cancer cure

Publications (1)

Publication Number Publication Date
MX2009011207A true MX2009011207A (es) 2009-12-07

Family

ID=38445838

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011207A MX2009011207A (es) 2007-04-17 2008-04-17 Eteres de amidas de acido naftalen-carboxilico como cura para el cancer.

Country Status (11)

Country Link
US (1) US8217045B2 (es)
EP (1) EP2146964A2 (es)
JP (1) JP2010524885A (es)
KR (1) KR20100016584A (es)
CN (1) CN101687801B (es)
AU (1) AU2008237839B2 (es)
BR (1) BRPI0810028A2 (es)
CA (1) CA2683049A1 (es)
EA (1) EA200901377A1 (es)
MX (1) MX2009011207A (es)
WO (1) WO2008125691A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3079683A4 (en) 2013-12-13 2017-12-20 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
CN107098884A (zh) * 2016-02-19 2017-08-29 中国科学院上海药物研究所 一类取代的氨基吡啶类化合物及其制备和用途
CA3054161A1 (en) 2017-03-30 2018-10-04 F. Hoffmann-La Roche Ag Isoquinolines as inhibitors of hpk1
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof
CN113318110B (zh) * 2020-02-28 2023-08-11 上海润石医药科技有限公司 一种csf-1r激酶抑制剂的用途
WO2022049253A1 (en) * 2020-09-07 2022-03-10 Bayer Aktiengesellschaft Substituted n-heteroaryl-n-pyridinylacetamides as p2x4 modulators
WO2026006488A1 (en) * 2024-06-26 2026-01-02 Antinous Technology Company Limited Angiogenesis inhibitors and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6693097B2 (en) * 2001-11-30 2004-02-17 Synta Pharmaceuticals Corp. Pyrimidine compounds
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
TW200418466A (en) * 2002-11-06 2004-10-01 Smithkline Beecham Corp Chemical compounds
RU2006122853A (ru) 2003-11-28 2008-01-10 Новартис АГ (CH) Производные диарилмочевины для лечения заболеваний, зависимых от протеинкиназы
KR20070026390A (ko) * 2004-01-23 2007-03-08 암젠 인코포레이션 화합물 및 사용방법
PE20060664A1 (es) * 2004-09-15 2006-08-04 Novartis Ag Amidas biciclicas como inhibidores de cinasa
GT200600411A (es) * 2005-09-13 2007-05-21 Novartis Ag Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascular
GB0605120D0 (en) 2006-03-14 2006-04-26 Novartis Ag Organic Compounds
JP2009532440A (ja) * 2006-04-07 2009-09-10 ノバルティス アクチエンゲゼルシャフト ａ）ピリミジルアミノベンズアミド化合物、およびｂ）Ｔｈｒ３１５Ｉｌｅキナーゼ阻害剤を含む、組合せ剤

Also Published As

Publication number Publication date
EA200901377A1 (ru) 2010-06-30
BRPI0810028A2 (pt) 2014-10-21
WO2008125691A2 (en) 2008-10-23
KR20100016584A (ko) 2010-02-12
US20100113467A1 (en) 2010-05-06
CA2683049A1 (en) 2008-10-23
US8217045B2 (en) 2012-07-10
CN101687801B (zh) 2012-10-03
AU2008237839A1 (en) 2008-10-23
AU2008237839B2 (en) 2012-02-02
WO2008125691A3 (en) 2009-02-05
CN101687801A (zh) 2010-03-31
JP2010524885A (ja) 2010-07-22
EP2146964A2 (en) 2010-01-27

Similar Documents

Publication Publication Date Title
MX2011005934A (es) Compuestos organicos.
MX2010007587A (es) Compuestos que comprenden un grupo ciclobutoxi.
NZ597517A (en) 5-fluoropyrimidinone derivatives
TN2009000509A1 (en) Pyrazole carboxylic acid amides useful as microbiocides
MX2012007098A (es) Derivados fenolicos y su uso farmaceutico o cosmetico.
NZ705135A (en) Heteroaryl compounds and methods of use thereof
MY153915A (en) Organic compounds
IN2012DN00692A (es)
MX2012007161A (es) Derivados fenolicos y su uso farmaceutico o cosmetico.
MX2011008864A (es) Tetrahidroazolopirazinas sulfoniladas y su uso como productos medicinales.
MX2009013276A (es) Compuestos anti-inflamatorios de ciclobutenodiona sustituida.
MX2011007998A (es) Nuevos herbicidas.
MY161132A (en) Novel herbicides
CR10955A (es) Nuevo procedimiento de sintesis de la agomelatina
UA102289C2 (ru) Гербициды, полученные из циклопентадиона
MX2009011207A (es) Eteres de amidas de acido naftalen-carboxilico como cura para el cancer.
MX2011007932A (es) Herbicidas nuevos.
NZ597570A (en) N1-acyl-5-fluoropyrimidinone derivatives
CR10960A (es) Nuevo procedimiento de sintesis de la agomelatina
IN2012DN00695A (es)
NZ597483A (en) N1-substituted-5-fluoro-2-oxopyrimidinone-1(2h)-carboxamide derivatives
MX2013007647A (es) Purificacion de torrentes de productos de acido acetico.
MX2011007266A (es) Microbiocidas nuevos.
PH12012501153A1 (en) Process for synthesis of intermediates useful for making substituted indazole and azaindazole compounds
MY156550A (en) Carboxylic acid derivatives having a 2,5-substituted oxazolopyrimidine ring

Legal Events

Date Code Title Description
HH Correction or change in general
FA Abandonment or withdrawal